drugset / Trial / NCT07414784

A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives

NCT07414784

Phase 1 Active not recruiting 20 enrolled AbbVie
NaSingle-groupOpen-labelTreatment

Summary

This Study of ABBV-295 subcutaneous injections will assess pharmacokinetics and adverse events in healthy adult women participants with overweight or obesity taking oral contraceptives.

Timeline

Start
2026-02-11
Primary completion
2026-07
Completion
2026-07

Drugs

EvaluationDrugModalityDoseRoute
Subject ABBV-295 Unknown Subcutaneous
Subject Levonorgestrel Small molecule Oral
Subject ethinyl estradiol Small molecule Oral

Indications

No indication recorded.